Perception here is not a survey — it is 79,000 evidence snippets extracted from what patients, clinicians and reviewers actually wrote and said, each carrying sentiment, an emotional register and a voice (first-person patient vs professional). Quotes below are verbatim from the corpus.
The leaderboard that matters
Sentiment by decision axis (−1 to +1), the axes patients actually decide on:
| Axis | Mounjaro | Wegovy | Ozempic | Semaglutide (API) |
|---|---|---|---|---|
| Efficacy & results | +0.55 | +0.54 | +0.42 | +0.51 |
| Cost & access | +0.45 | +0.44 | +0.35 | +0.39 |
| Dosing & device | +0.30 | +0.32 | +0.15 | +0.24 |
| Side effects | −0.06 | −0.12 | −0.32 | −0.24 |
| Regain after stopping | +0.45 | +0.07 | −0.01 | −0.34 |
| Trust & safety | +0.44 | +0.39 | +0.16 | +0.16 |
Everyone wins on efficacy — that argument is over. The moat is regain: the tirzepatide family owns a positive "keeping it off" conversation while the semaglutide family carries the regain anxiety. That, and near-neutral tolerability, is Mounjaro's perception advantage — worth more than any spec.
One molecule breaks the pattern: retatrutide, not yet launched, is the only one whose dominant emotional register is aspiration (30% of its mentions) — the market is pre-selling itself the next upgrade.
In their own words
Patients — the results that pull people in:
"Now, here I am 76 pounds down and looking and feeling so much better." — Reddit "FIFTY POUNDS in 8 months." — Reddit
Patients — the friction that pushes back:
"After answering a few dozen health-related questions online, I was approved for Ozempic. At no point did I speak on the phone to anyone." — YouTube
Clinicians — conviction and caution in the same corpus:
"We are in the beginning of the most effective medical intervention for obesity that we've ever seen in our lives." — YouTube (physician) "I've seen my patients getting ischemic optic neuropathies after starting these meds." — Reddit (medical professional)
The hard edges:
"Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC)…" — official labelling, quoted in the corpus "Counterfeit Ozempic has been found to contain insulin instead of semaglutide." — web article
The diabetes thread
These are diabetes drugs first — semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro) are licensed for type-2 diabetes, re-licensed for weight loss. The crossover is live in the evidence ("I started MJ for T2D and weight loss"), it drove the 2023 diabetic-supply shortages, and it imports the insulin/sulfonylurea interaction and hypoglycaemia risks into the weight-loss conversation. Content that ignores the dual indication misreads the audience.